摘要
Systemic lupus erythematosus (SLE) is a female predominant autoimmune disease characterized by multi-organ disorders. The pathogenesis of SLE is complex. Corticosteroids and immunosuppressive drugs are widely used to treat patients with SLE. However, these indiscriminate suppressors of the immune-mediated inflammatory aberration treat SLE at the cost of considerable adverse effects. Undoubtedly, there is a need for safer and more effective treatments for SLE. Cell-based therapies, although very much in their infancy, are of increasing interest in the treatment of SLE due to their potential for long-term suppression or a possible cure of the disease. Several immunoregulatory cell types, including regulatory T cells, mesenchymal stem cells, B-cells and natural killer cells, have recently been developed as novel products for tolerance-promoting therapies. Here, we provide a brief overview of current research of new cell-based therapeutic approaches that have undergone pre-clinical or clinical trials in the treatment of SLE.
- Exosomes as Crucial Players in Pathogenesis of Systemic Lupus ErythematosusFei, Yue; Liu, Qi; Peng, Na; Yang, Guocan; Shen, Ziwei; Hong, Pan*; Wang, Shengjun*; Rui, Ke*; Cui, Dawei*Journal of Immunology Research, 2022, 2022: 8286498.被引 4
- Targeting abnormal lipid metabolism of T cells for systemic lupus erythematosus treatmentHu, Jia-Qin; Yan, Yan-Hua; Xie, Han; Feng, Xue-Bing; Ge, Wei-Hong; Zhou, Hua; Yu, Li-Li*; Sun, Ling-Yun*; Xie, Ying*Biomedicine and Pharmacotherapy, 2023, 165: 115198.
- Exosome Derived from Human Umbilical Cord Mesenchymal Cell Exerts Immunomodulatory Effects on B Cells from SLE PatientsZhao, Ying; Song, Wenbin; Yuan, Zilin; Li, Min; Wang, Gang; Wang, Liping; Liu, Yueping*; Diao, Bo*Journal of Immunology Research, 2023, 2023: 3177584.被引 4
